Grand Programme Fédérateur Vaccinologie
Désolé, cet article est seulement disponible en Anglais Américain.
Think tank: Cancer
The malignant transformation of cells translates into a major worldwide health, social and economic burden. Efforts to define the etiology of cancer, along with the development of new therapeutic approaches to treat them, would […]
Advanced Immunization Technologies (ADITEC)
We are member of the ADITEC Consortium, a collaborative research programme that aims to accelerate the development of novel and powerful immunisation technologies for the next generation of human vaccines. Scientists from 13 countries […]
GPF Vaccinology Call 1: Open call for new ideas for cutting-edge science investigations in vaccinology.
The purpose of this call for ideas is to solicit community input for original, cutting-edge science investigations that are consistent with the Institut Pasteur’s new development strategy in vaccinology. The “Open Pasteur vaccine challenge” […]
GPF Vaccinology Call 2: Accelerating Preclinical Development of Vaccine Candidates
With the second call, the GPF Vaccinology aims at identifying ongoing preclinical projects aiming to develop vaccine candidates at Institut Pasteur, including the International Network. The objective of the GPF call is to help […]
A synthetic glycopeptide for anti-tumor immunotherapy: from design to first use in human
Within the framework of developing a carbohydrate-based vaccine against cancer, we designed and prepared the MAG-Tn3, a fully synthetic immunogen based on the tumor-associated Tn antigen. The MAG-Tn3 is a glycopeptide associating Tn clusters […]
Comics on vaccination
The Center for Translational Science, the Center Medical Institut Pasteur (CMIP) and the major federating program (GPF) vaccinology welcome for one year a science illustrator, Celia Ducaju, in partnership with the Ecole Estienne School […]
Clinical development of cancer vaccines
CyaA-based therapeutic cancer vaccines Based on our discovery that a bacterial protein, the adenylate cyclase (CyaA), binds to dendritic cells (DCs), we have developed a highly efficient vector capable of targeting a wide range […]
Tumor immunity and preclinical development of cancer vaccines
Human Papillomaviruses (HPV) are the major cause of human cervical cancer. We have developed a therapeutic tumor vaccine, the CyaA-E7 vaccine, that can induce specific responses against the HPV E7 oncoprotein and eliminate E7 […]
2018Mitochondrial reactive oxygen species regulate the induction of CD8 T cells by plasmacytoid dendritic cells, Nat Commun 2018 Jun;9(1):2241.
2018Mitochondrial reactive oxygen species regulate the induction of CD8+ T cells by plasmacytoid dendritic cells., Nat Commun. 2018 Jun 8;9(1):2241.
2018Tumor-Derived TGFβ Alters the Ability of Plasmacytoid Dendritic Cells to Respond to Innate Immune Signaling., Cancer Res. 2018 Jun 1;78(11):3014-3026.
2018Tumor-Derived TGFβ Alters the Ability of Plasmacytoid Dendritic Cells to Respond to Innate Immune Signaling, Cancer Res. 2018 Jun;78(11):3014-3026.
2017Colonization with Helicobacter is concomitant with modified gut microbiota and drastic failure of the immune control of Mycobacterium tuberculosis, Mucosal Immunol 2017 Sep;10(5):1178-1189.
2016A Universal Influenza Vaccine Can Lead to Disease Exacerbation or Viral Control Depending on Delivery Strategies, Front Immunol 2016;7:641.
2016Large-scale synthesis and structural analysis of a synthetic glycopeptide dendrimer as an anti-cancer vaccine candidate, Org. Biomol. Chem. 2016 Dec;15(1):114-123.
2016CD4+ T Cells Recognizing PE/PPE Antigens Directly or via Cross Reactivity Are Protective against Pulmonary Mycobacterium tuberculosis Infection, PLoS Pathog. 2016 Jul 28;12(7):e1005770. doi: 10.1371/journal.ppat.1005770..
2016B cells promote tumor progression in a mouse model of HPV-mediated cervical cancer, Int. J. Cancer 2016 Sep;139(6):1358-71.
2016The fully synthetic MAG-Tn3 therapeutic vaccine containing the tetanus toxoid-derived TT830-844 universal epitope provides anti-tumor immunity, Cancer Immunol. Immunother. 2016 Mar;65(3):315-25.
+Voir la liste complète de publications